一份基于近6万名患者的Medicare数据显示，诺和诺德的Ozempic在降低心脏病发作、中风和死亡风险方面比礼来的Trulicity低23%。受此消息提振，诺和诺德股价飙升超7%。在此之前，礼来凭借Mounjaro和Zepbound已对其构成巨大竞争压力。在一场备受关注的药物对决中，诺和诺德取得了关键性胜利。一项涉及近6万名糖尿病和心脏病患者的Medicare数据研究显示，使用Ozempic的...
Source Link一份基于近6万名患者的Medicare数据显示，诺和诺德的Ozempic在降低心脏病发作、中风和死亡风险方面比礼来的Trulicity低23%。受此消息提振，诺和诺德股价飙升超7%。在此之前，礼来凭借Mounjaro和Zepbound已对其构成巨大竞争压力。在一场备受关注的药物对决中，诺和诺德取得了关键性胜利。一项涉及近6万名糖尿病和心脏病患者的Medicare数据研究显示，使用Ozempic的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.